The total net revenues of AbbVie's Rinvoq and Skyrizi were about $25.87 billion in 2025, up 46.2% from 2024. Read why ABBV ...

Cory Fortier was just nine, when he was diagnosed with uveitis, an often painful form of arthritis of the eye.

Shares of AbbVie (ABBV) lost ~7% on Wednesday after the Chicago-based pharma giant posted better-than-expected Q4 2025 results, which, according to BNP Paribas, were driven by its older blockbuster ...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. AbbVie (NYSE:ABBV) has agreed to acquire Capstan ...

Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising superstar Skyrizi. Despite the fall of what was once the world’s top-selling ...

AbbVie expects $31.6 billion from Rinvoq, Skyrizi in 2026 Shares fall 6% after Rinvoq's Q4 sales miss Skyrizi sales surpass expectations with $5.01 billion Feb 4 (Reuters) - AbbVie (ABBV.N), opens new ...

Country music's most prolific touring band will hit the road again this summer. The Zac Brown Band just announced the Love & Fear Tour. The band's 27-date run begins in Grand Rapids, Mich. on July 17 ...

The company sure knows what to do before and after a blockbuster drug tumbles off the patent cliff. AbbVie had many factors lifting its business, and what's more, these are likely to continue at least ...

Investors pummeled AbbVieABBV stock Wednesday after the company delivered a fourth-quarter sales beat that came largely on the back of still-declining Humira sales. Once key to AbbVie's top line, ...

NPR's Scott Simon speaks to incorrigible Canadians Matt Johnson and Jay McCarrol about their new film, "Nirvanna: The Band - the Show - the Movie." "Nirvanna The Band The Show The Movie" is a new ...

Original Medicare covers most medically necessary treatments for rheumatoid arthritis (RA), including biologics like adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Inflectra), and ...